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Objectives. Osteopontin (OPN) is overexpressed in breast cancers, while its clinical and prognostic significance remained unclear.
This study aimed to assess the prognostic value of OPN, especially its splice variants, in breast cancers.Methods.Data were extracted
from eligible studies concerning theOPN andOPN-c expression in breast cancer patients andwere used to calculate the association
between OPN/OPN-c and survival. Two reviewer teams independently screened the literatures according to the inclusion and
exclusion criteria based on quality evaluation. Following the processes of data extraction, assessment, and transformation, meta-
analysis was carried out via RevMan 5.3 software. Results. A total of ten studies involving 1,567 patients were included. The results
demonstrated that high levelOPN indicated a poor outcome in theOS (HR= 2.22, 95%CI: 1.23–4.00, and𝑃 = 0.008; random-effects
model) with heterogeneity (𝐼2 = 62%) of breast cancer patients. High level OPN-c appeared to be more significantly associated
with poor survival (HR = 2.14, 95% CI: 1.51–3.04, and 𝑃 < 0.0001; fixed-effects model) with undetected heterogeneity (𝐼2 = 0%).
Conclusions. Our analyses indicated that both OPN and OPN-c could be considered as prognostic markers for breast cancers. The
high level of OPN-c was suggested to be more reliably associated with poor survival in breast cancer patients.
1. Introduction
Breast cancer is one of the most commonly diagnosed
cancers in women worldwide and it is the leading cause of
cancer death. According to the statistics provided by the
American Cancer Society, approximately 231,840 new cases
of invasive breast cancer and 40,290 breast cancer deaths
occurred among US women in 2015 [1]. It was estimated by
GLOBOCAN 2008 that breast cancer was the most frequent
cancer in Chinese women, with an age standardized rate
(ASR) of 21.6 cases per 100,000 individuals [2]. Although
multiple treatment methods including surgery, chemother-
apy, radiotherapy, and targeted therapy have been applied
over the past few decades, the prognosis of breast cancer
remains unsatisfactory. Due to the limitations in prognostic
values of the conventional predicting factors, such as TNM
stage, age, sex, and histological type, it is necessary to explore
novel biomarkers to better predict the outcome and assist in
the clinical management of breast cancer patients.
Osteopontin (OPN), a phosphorylated glycoprotein
secreted by various tissues and cells, has been implicated
with important roles in physiological and pathological
processes [13–15]. In recent years, accumulating evidences
have shown that aberrant OPN expression was closely
associated with tumorigenesis andmetastasis in several types
of tumors, including breast cancer [16, 17]. Overexpression
of OPN was found in multiple malignant breast cancer
cell lines, and the transfection of OPN into benign breast
epithelial cells induced invasive behavior [18]. In addition,
several studies investigated the association between OPN
expression and the clinical outcome and prognosis of
breast cancer patients, but the results failed to demonstrate
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a consented conclusion regarding the ability of OPN to
predict cancer progression [7, 19–21].
The biological functions of metastasis-associated gene
products are often mediated by different splicing isoforms.
Alternative splicing OPN secreted by various cells has diverse
structural characteristics. Tumor-derived OPN forms are
smaller than OPN secreted by nontransformed cells. Full
length OPN (OPN-a) consists of 7 exons while OPN-b
and OPN-c lack exon 4 and exon 5, respectively [22, 23].
Alternative splicing occurred at the upstream of the central
integrin binding domain and the C-terminal CD44 binding
domain [24–26]. Clinical data suggested that the shortest
splice variant OPN-c could be a selective diagnostic and
prognostic candidate for human breast cancer [27–29]. How-
ever, the clinical function of OPN-c in breast cancer remains
poorly defined.
Therefore, to clarify the prognostic significance of OPN,
as well as its splicing variants, in breast cancer, it is necessary
to investigate the association of OPNs expressionwith patient
survivals. In the present study, we pooled data from the
available reports and analyzed the association between the
expression of OPN and the prognostic measures of breast
cancer patients.
2. Materials and Methods
2.1. Study Selection. Acomprehensive literature search (dated
to December 2015) was conducted through the PubMed
database.The query strategy was the combinations of the fol-
lowing terms: “Osteopontin”, “OPN”, “OPN-c”, “Osteopon-
tin-c”, “breast cancer”, “prognosis”, “prognostic” and “sur-
vival” without restrictions on regions, languages, and publi-
cation types. All eligible studies were retrieved.
2.2. Inclusion and Exclusion Criteria. The criteria for ref-
erence inclusion were (1) data associated with OPN lev-
els (negative/positive or low/high expression), as measured
by reverse transcription-polymerase chain reaction (RT-
PCR), immunohistochemistry (IHC), or enzyme linked
immunosorbent assay (ELISA); (2) confirmed diagnosis of
breast cancer with pathological or histological evidence; (3)
hazard ratio (HR) and their 95% confidence intervals (CIs)
that could be directly extracted or disease-free survival or
overall survival with sufficient data that was provided; (4)
some data supplied by authors upon our requests for the
calculation of the HR or 95% CIs values.
The studies were excluded for (1) meeting abstracts,
letters, case reports, and reviews; (2) being animal studies;
(3) missing necessary data; and (4) using redundant or
overlapped database records.
2.3. Data Extraction and Quality Assessment. To reduce bias
and improve reliability, two investigator groups indepen-
dently reviewed potentially relevant studies. The data of the
number of patients, follow-up, detection method, and cut-
off value, together with name of the first author, name of
the journal, year of publication, and ethnicity, were extracted
and then analyzed against OPN/OPN-c expression-related
survival. Conflicting interpretation problems were resolved
through consensus with the third investigator. The outcome
assessment focused on survival curves in patients with
different OPN/OPN-c expression. The GetData Graph Dig-
itizer 2.24 software (http://getdata-graph-digitizer.com/) and
HR digitizer Engauge 4.1 software (http://engauge-digitizer
.software.informer.com/) were used to digitize and extract
the data from the Kaplan-Meier curves, in cases when
only survival curves were provided. The quality of each
included studywas based on two independent assessments by
Newcastle-Ottawa Scale (NOS) scoring. We allocated a score
of 0–9 to each included study, and those with a NOS score ≥
6 were assigned as high-quality studies.
2.4. Statistical Analysis. Theassociation betweenOPN/OPN-
c expression and the survival outcome of breast cancer was
estimated according to the HR and 95% CI directly or indi-
rectly extracted from each eligible study. The heterogeneity
among studies was detected using Cochran’s 𝑄 test and
Higgins 𝐼-squared statistic. Severe heterogeneity was taken
into account based onmeasures of 𝐼2 > 50%.The fixed-effects
model was used when 𝐼2 < 50% or 𝑃 ≥ 0.10 in the 𝑄 test,
while random-effects model was conducted otherwise. The
potential publication bias was estimated by Egger’s and Begg’s
tests with significance of 𝑃 < 0.05. All the statistical analyses
were performed using Review Manager version 5.3.
3. Results
3.1. Characteristics of Included Studies. Following the search
strategy given in Section 2, a total of 214 potentially relevant
citations were retrieved (Figure 1). After reviewing the titles
and abstracts, 188 studies failed to meet our selection criteria
and were excluded. The remaining 26 were subjected to
full-text screening, of which 16 publications were excluded
because of the lack in survival or follow-up data associated
with OPN/OPN-c. Eventually, a total of 10 studies including
1,567 patients were qualified for further analysis, 7 of which
investigated the impact of OPN expression on survival and 4
were about OPN-c.Three of the 10 studies used ELISA, 5 used
IHC, and 2 used qRT-PCR to detect serum- or tissue-derived
OPN/OPN-c expression. Detailed values from the included
publications were summarized in Table 1.
3.2. Association of OPN on OS of Breast Cancer Patients.
Seven included studies provided data for calculating the
association betweenOPNexpression and survival.Wepooled
all the available data into our meta-analysis and found that
poor OS was significantly associated with a positive status
for OPN (HR = 2.22, 95% CI: 1.23–4.00, and 𝑃 = 0.008)
(Figure 2), with heterogeneity in the data (𝐼2 = 62%, 𝑃 =
0.01).
To determinewhether the heterogeneity inOSwas caused
by data bias, we performed sensitivity analysis to assess the
stability of the results.The results showed that, after exclusion
of the study by Liao et al., the heterogeneity for OS did
not significantly decrease (𝐼2 = 56%, 𝑃 = 0.0007) with a
combined HR of 2.64 (95% CI: 1.51–4.63) (Figure 3). The fact
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Publications 
identified on the basis 
of searching strategies 
Publications 
excluded by title 
Articles included for 
Exclude articles 
full-text review 
Articles included for 
final quantitative 
86 about cells
18 review articles
84 about animals
5, survival data not shown 
sufficiently
6, about treatment
5, with other reasons
(n = 214)
or abstract (n = 188)
full-text review (n = 26)
analysis (n = 10)
(n = 16) after
Figure 1: Flowchart of the selection process of studies for inclusion
in this meta-analysis.
that the HR and 𝐼2 values were not significantly altered with
the exclusion of distracted dataset indicated that the method
was appropriate and the results were credible.
The subgroup meta-analyses were performed to exclude
the potential influence from sample heterogeneity. Four
studies (three using IHC, one by qPCR) were included to
evaluate the connection between OPN expression in breast
tumor tissues and survival. Positive OPN expression was
associated with poor OS (HR = 2.10, 95% CI: 0.81–5.43) with
heterogeneity (𝐼2 = 80%, 𝑃 = 0.002), but no significant
difference (𝑃 = 0.13) was found (Figure 4). Three studies
about the association between plasmaOPN level and survival
were also investigated. Results showed that reduced survival
was significantly associated with a positive status for plasma
OPN (HR = 2.46, 95% CI: 1.31–4.60, and 𝑃 = 0.005)
(Figure 5), with diminished heterogeneity in the data (𝐼2 =
0%, 𝑃 = 0.76).
3.3. Association of OPN-c on Survival of Breast Cancer
Patients. Four studies (two OS, one on DFS, and one with
five-year survival) including 853 patients were investigated.
The statistical results once again indicated that high OPN-c
expression in tissues was significantly associated with poor
survival (HR = 2.14, 95% CI: 1.51–3.04, and 𝑃 < 0.0001) with
diminished heterogeneity (𝐼2 = 0%, 𝑃 = 0.72) (Figure 6).
3.4. Publication Bias. In order to assess the publication bias
of the included studies, Begg’s funnel plot was deployed. As
shown in Figures 7 and 8, nonasymmetric funnel plots for the
synthesis of the HRs for survival were obtained. Hence, no
publication bias was detected among all the comparisons.
4. Discussion
As a popular and effective approach for systematic reviews,
meta-analysis has been successfully applied to evaluate
prognostic indicators in patients with varied diseases. It
has been indicated in recent research that the expression
of biomarkers was promisingly associated with tumor pro-
gression, including breast cancers. Besides, its elevated levels
often suggested high tumor grade, metastasis, and poor
prognosis. Several markers have been used in breast cancer
diagnosis, including estrogen receptor (ER) and progesterone
receptor (PR). However, these markers still lack the adequate
sensitivity and specificity for detecting prognosis of breast
cancer patients. It was reported that OPN might be a more
potential clinicalmarker candidate for predicting the survival
of breast cancer patients than ER and PR [6, 7, 9]. A meta-
analysis was further performed in our group to clarify the
above ambiguous conclusion and to investigate the associa-
tion of OPN with prognostic factors in breast cancer.
From a number of reports, OPN was overexpressed in
primary tumors and maintained a high secreted level in the
blood of breast cancer patients, which correlated with a poor
prognosis [3–6, 8, 9, 30]. The results of our present meta-
analysis study basically supported the association between
increased OPNs with poor OS in patients with breast cancer
(𝑃 = 0.008). However, there could be a concern with the
heterogeneity (𝐼2 = 62%). Through the sensitivity analysis,
the resulting heterogeneity value (𝐼2 = 56%) without substan-
tial changes indicated an intrinsic property and would not
compromise the robustness and prognostic values of OPN in
breast cancer.Theheterogeneity problemwas also reported in
a recent similar meta-analysis conducted by Xu et al., which
explored the prognostic value of OPN by OS and DFS in
breast cancer patients. Notably, the further subgroup analysis
showed that the increased OPN was not correlated with
clinicopathological parameters such as tumor grade, tumor
stage, PR status, ER status, and p53 status, suggesting that
the source of heterogeneity could be rather complicated [31].
The prognostic value of OPN has been reported in systematic
reviews and meta-analyses on lung [32], colorectal [33], and
pancreatic [34] cancers with a vast range in heterogeneities
and the positive association of increased OPN with the
survival of cancer patients appeared to be consistent, despite
the fact that certain additional factors were indeed to be
considered for the statistical analysis of heterogeneity and its
origins.
Alternative RNA splicing of human OPN results in
three transcriptive variants: OPN-a (full length), OPN-b
(lacking exon 5), and OPN-c (lacking exon 4). Recent studies
have shown that cell-type specific expression of OPN splice
variants exerted different functions in malignant tumors.
Compared to full length OPN, OPN-c was specifically
expressed in breast cancer cells. Hence, it was likely to be
a better prognostic marker for human breast cancer [9–12].
Unfortunately, studies have not conducted separate measures
on OPN splice variants. The results were actually the total
OPN (including OPN-a, OPN-b, and OPN-c) expression in
plasma or tumor of breast cancer patients. The only study
that can be found reported that the survival for breast cancer
patients with high levels of OPN-b mRNA expression was
found to differ significantly from that of their low level
counterparts [12]. The available data of OPN-c for cancer
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Study ID HR (95% CI) Weight
Note: weights are from
random-effects analysis
10.1 10
Ortiz et al. 2014
Singha et al. 1997
Liao et al. 2010
Martinetti et al. 2004
Anborgh et al. 2015
Rudland et al. 2002
Tuck et al. 1998
6.42 [2.93, 14.07] 17.3%
3.22 [1.31, 7.94] 15.7%
1.28 [0.71, 2.31] 19.9%
0.58 [0.16, 2.08] 11.5%
2.20 [0.89, 5.43] 15.7%
3.06 [1.20, 7.85] 15.2%
1.28 [0.11, 14.88] 4.7%
2.22 [1.23, 4.00] 100%Overall (I2 = 62%, P = 0.008)
Figure 2: Forest plot demonstrating the association of OPN expression with overall survival in breast cancer. HR, hazard ratio; CI, confidence
interval.
Study ID HR (95% CI) Weight
Note: weights are from 
random-effects analysis
10.1 10
1.28 [0.11, 14.88] 4.5%
3.06 [1.20, 7.85] 16.9%
3.22 [1.31, 7.94] 17.6%
2.20 [0.89, 5.43] 17.6%
6.42 [2.93, 14.07] 19.7%
1.28 [0.71, 2.31] 23.7%
2.64 [1.51, 4.63] 100%Overall (I2 = 56%, P = 0.0007)
Ortiz et al. 2014
Singha et al. 1997
Martinetti et al. 2004
Anborgh et al. 2015
Rudland et al. 2002
Tuck et al. 1998
Figure 3: Forest plot on the association between OPN expression and overall survival in breast cancer by sensitivity analysis. HR, hazard
ratio; CI, confidence interval.
survival only allowed primitive comprehensive analysis. In
the present study, we carried out a meta-analysis and noted
that the high level ofOPN-cwas associatedwith poor survival
with better statistical significance (𝑃 < 0.0001) and, most
of all, with a drastically reduced heterogeneity (𝐼2 = 0%).
Thus, OPN-c could be by far a most significant predictor of
the poor prognosis of breast cancers, which could be further
investigated in studies involving more breast cancer patients
or perhaps in other cancer types as well.
Interestingly, in the subgroup meta-analysis, positive
OPN expression in breast tumor tissues was associated with
poor OS, but no significant difference (𝑃 = 0.13) was found
(Figure 4), while reduced survival was significantly associated
with a positive status for OPN in plasma (𝑃 = 0.005)
(Figure 5). These results seemed to be contrary; however,
they were still considered to confirm the results that the
total tumor OPN expression was very heterogeneous. As
a more significant marker candidate, OPN-c is likely to
be of particular utility as a prognostic marker and should
be included in further validation studies. The significant
association between plasma OPN and survival suggested
that the plasma detection could be a powerful supplement
to the analysis of tumor tissues. However, there were no
reports about the association between plasma OPN-c and
the prognosis of breast cancers till now. Therefore, it is
very important and necessary to perform the corresponding
studies.
We have recognized that there are several limitations
existing in this meta-analysis. First, the literatures covering
this topic are limited in numbers. The database documenting
their related data is small in scale, especially those about
OPN-c. Second, the investigation regarding the correlations
between OPN/OPN-c expression and clinical features, such
as tumor stage, lymph node metastasis, and tumor size, is
not performed, because most of the primary studies have
not provided sufficient information for this analysis. Third,
different methods are adopted and inconsistent cut-off values
are used for determining the expression of OPNs in different
reports, and therefore it is a challenge for the normalization
of the results. Fourth, in dealing with the reports which do
not contain the HRs in the full text, we extrapolated the
values from the survival curves. Although this approach is
6 BioMed Research International
Study ID HR (95% CI) Weight
10.1 10
Note: weights are from
random-effects analysis
0.58 [0.16, 2.08] 20.3%
1.28 [0.71, 2.31] 28.5%
3.22 [1.31, 7.94] 24.9%
2.10 [0.81, 5.43] 100%
6.42 [2.93, 14.07] 26.3%
Overall (I2 = 80%, P = 0.13)
Ortiz et al. 2014
Liao et al. 2010
Rudland et al. 2002
Tuck et al. 1998
Figure 4: Forest plot demonstrating the association of OPN expression with overall survival in tissues of breast cancer patients. HR, hazard
ratio; CI, confidence interval.
Study ID HR (95% CI) Weight
10.1 10
Note: weights are from
fixed-effects analysis
2.19 [0.89, 5.38] 48.8%
3.05 [1.20, 7.80] 44.7%
1.28 [0.11, 14.88] 6.5%
2.46 [1.31, 4.60] 100%Overall (I2 = 0%, P = 0.005)
Singha et al. 1997
Martinetti et al. 2004
Anborgh et al. 2015
Figure 5: Forest plot demonstrating the association of OPN expression with overall survival in blood of breast cancer patients. HR, hazard
ratio; CI, confidence interval.
Study ID HR (95% CI) Weight
10.1 10
Note: weights are from
fixed-effects analysis
2.19 [1.18, 4.06] 32.3%
Pang et al. 2013 2.56 [1.05, 6.25] 15.5%
Patani et al. 2008 4.09 [0.98, 17.10] 6.0%
Zduniak et al. 2015 1.82 [1.09, 3.06] 46.2%
2.14 [1.51, 3.04] 100%Overall (I2 = 0%, P < 0.0001)
Ortiz et al. 2014
Figure 6: Forest plot demonstrating the association of OPN-c expression with overall survival in breast cancer. HR, hazard ratio; CI,
confidence interval.
a common practice, we cannot exclude the possible intro-
duced errors. Finally, to avoid the potential publication bias,
factors, such as sex, age, and geographical origins, are not
considered in this analysis.
In summary, both OPN and OPN-c could be considered
as markers for breast cancer prognosis. The finding of better
performance of OPN-c in statistics suggested that the strat-
ification of different isoforms or variants of gene expression
could be a valid approach for searching better biomarkers in
cancer patients. Based on the findings from this study, we
recommend a prospective study to confirm the prognostic
value of OPN-c in breast cancer patients.
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Figure 7: Begg’s funnel plot estimating the publication bias of the
included studies about OPN. HR, hazard ratio.
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Figure 8: Begg’s funnel plot estimating the publication bias of the
included studies about OPN-c. HR, hazard ratio.
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